← Back to Search

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Phase 2
Waitlist Available
Led By Te Vuong, MD
Research Sponsored by Dr. Te Vuong
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month post end of treatment
Awards & highlights
No Placebo-Only Group

Summary

The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.

Eligible Conditions
  • Anal Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month post end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month post end of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Local tumor response rate
Toxicity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NimotuzumabExperimental Treatment2 Interventions
Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intensity Modulated Radiation Therapy (IMRT)
2010
Completed Phase 1
~60
Nimotuzumab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Dr. Te VuongLead Sponsor
2 Previous Clinical Trials
2 Total Patients Enrolled
YM BioSciencesIndustry Sponsor
13 Previous Clinical Trials
1,165 Total Patients Enrolled
Te Vuong, MDPrincipal InvestigatorJewish General Hospital
6 Previous Clinical Trials
422 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top